MedTrace Logo

Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma

NCT05211232 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 450

Last updated 2024-04-18

No results posted yet for this study

Summary

The purpose of this study is to explore the efficacy and safety of a combination of GP chemotherapy and tislelizumab in neoadjuvant therapy combined with tislelizumab in adjuvant therapy of locoregionally advanced nasopharyngeal carcinoma patients.

Conditions

  • Nasopharyngeal Carcinoma

Interventions

DRUG

Tislelizumab

GP combine with Tislelizumab neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy

DRUG

Placebo

GP combine with Placebo neoadjuvant therapy+CCRT+Tislelizumab adjuvant therapy

Sponsors & Collaborators

  • Cancer Hospital of Guizhou Province

    collaborator OTHER

  • Hunan Cancer Hospital

    collaborator OTHER

  • Wuzhou Red Cross Hospital

    collaborator OTHER

  • Affiliated Hospital of Guangdong Medical University

    collaborator OTHER

  • Sun Yat-sen University

    lead OTHER

Principal Investigators

  • haiqiang Mai, MD · Sun Yat-sen University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-06-10
Primary Completion
2026-05-30
Completion
2028-05-30

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05211232 on ClinicalTrials.gov